Uma breve revisão dos complexos transplatínicos na terapêutica oncológica

Abstract

Drugs with potential antitumor activity are of great interest to the pharmaceutical industry, since cancer is one of the diseases that affect thousands of people around the world. Cisplatin is a platinum (2+) compound widely used in cancer chemotherapy, with excellent rates of tumor regression, however, the severe side effects and cross-resistance limit its use. Thus, cisplatin analogues compounds such as carboplatin, nedaplatin, and oxaliplatin have been developed and clinically approved. Despite this, patients who use such drugs for treatment may develop cross-resistance. In this context, the need arose to search for new complexes that make it possible to minimize side effects and cross-resistance. Among the new platinum (2+) compounds of interest with antitumor activity studied, there are complexes with trans isomerism, which, due to their different mechanisms of action when binding to nDNA nucleophiles present promising strategies to overcome the mentioned difficulties encountered by current drugs with cis isomerism. Therefore, research on antitumor activity in platinum (2+) complexes with trans isomerism is relevant, to which this work is intended. This study consists of a brief review of the literature, allowing to map examples of transplatin complexes that stand out for their cytotoxic properties, configuring them as promising antineoplastic agents.